Ilumya Alternatives Compared
| Ilumya (tildrakizumab) | Stelara (ustekinumab) | Clobetasol topical |
|
|---|
| Ilumya (tildrakizumab) | Stelara (ustekinumab) | Clobetasol topical |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ilumya is administered by subcutaneous injection every 12 weeks (after an initial loading dose) and may be used to reduce inflammation associated with psoriasis but it needs to be administered by a... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Prescribed for Anal Itching, Dermatitis, Eczema, Atopic Dermatitis, Cutaneous T-cell Lymphoma, Psoriasis, Dermatological Disorders, Lichen Planopilaris, Lichen Planus, Lichen Sclerosus, Necrobiosis... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Ilumya (tildrakizumab) | More about Stelara (ustekinumab) | More about Clobetasol topical | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Ilumya has an average rating of 5.8 out of 10 from a total of 8 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 38% reported a negative effect. |
Stelara has an average rating of 7.7 out of 10 from a total of 251 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 15% reported a negative effect. |
Clobetasol topical has an average rating of 8.3 out of 10 from a total of 162 ratings on Drugs.com. 79% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ilumya prices |
View all Stelara prices |
View all Clobetasol topical prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek | Clobevate, Clobex, Clodan, Cormax, Cormax Scalp, Dermovate, Embeline, Embeline E, Impeklo, Impoyz, Olux, Olux-E, Temovate, Temovate Emollient, Tovet View more | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
552 hours |
1291.2 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 178 drugs are known to interact with Ilumya:
|
A total of 533 drugs are known to interact with Stelara:
|
A total of 48 drugs are known to interact with Clobetasol topical:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
September 25, 2009 |
December 27, 1985 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.